Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Stephen L. Luen
Residual Disease and Immune Infiltration as a New Surrogate Endpoint for TNBC Post Neoadjuvant Chemotherapy
Oncotarget
Oncology
Related publications
Comedications Influence Immune Infiltration and Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer
OncoImmunology
Oncology
Allergy
Immunology
Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma
British Journal of Haematology
Hematology
Proposed Study Designs for Approval Based on a Surrogate Endpoint and a Post-Marketing Confirmatory Study Under FDA’s Accelerated Approval Regulations for Disease Modifying Osteoarthritis Drugs
Osteoarthritis and Cartilage
Sports Medicine
Rheumatology
Orthopedics
Biomedical Engineering
Surrogate Endpoint Biomarkers for Cervical Cancer Chemoprevention Trials
Journal of Cellular Biochemistry
Biochemistry
Cell Biology
Molecular Biology
Pcn290 - Use of PCR as a Surrogate Primary Endpoint in Drug Pivotal Trials in Neoadjuvant Early Breast Cancer in Eu: A Perspective From Regulators and Payers
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Rationale for Neoadjuvant Chemotherapy in the Management of Malignant Disease
Cervical Cancer Chemoprevention, Vaccines, and Surrogate Endpoint Biomarkers
Cancer
Cancer Research
Oncology
Serum Urate as Surrogate Endpoint for Flares in People With Gout: A Systematic Review and Meta-Regression Analysis
Seminars in Arthritis and Rheumatism
Rheumatology
Anesthesiology
Pain Medicine
Post-Neoadjuvant Treatment and the Management of Residual Disease in Breast Cancer: State of the Art and Perspectives
Therapeutic Advances in Medical Oncology
Oncology
